ADRB3 and Alzheimer disease: Studies have shown that β3AR agonists improve recognition memory and reduce hippocampal Aβ42/Aβ40 ratios in AD mouse models (Tournissac et al., 2021), effects that mirror the potential benefits of LINCS-identified procaterol, which has activity at both β2 and β3 receptors.